Industry

Company growth continues to fuel innovation and data integration across the care continuum MISSISSAUGA, Ontario–(BUSINESS WIRE)–PointClickCare Technologies, a leading healthcare technology platform enabling meaningful collaboration and access to real‐time insights, today announced its recognition on the Globe and Mail’s 2022 Report of Canada’s Top Growing Companies for the fourth consecutive year. Canada’s Top Growing Companies … [Read more…]

SASKATOON, Saskatchewan–(BUSINESS WIRE)–#agribusiness–Modern society would not be possible without biotechnology. From vaccines and medicines, to crops, foods, cleaners, and industrial products, biotechnology benefits every area of our lives. In Saskatchewan, we celebrate Global Biotech Week to showcase the province’s scientific achievements and increase awareness of how science affects our lives. Ag-West Bio coordinates Global Biotech … [Read more…]

Complement C5 Antibody, CAN106, in Phase 1b/2 China Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH) BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals, Inc. (1228.HK), a China and U.S.-based global biopharmaceutical company committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, announced that it will be presenting data from the CAN106 … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Disinfectant and Antimicrobial Chemicals Market Size & Share to 2027” report has been added to ResearchAndMarkets.com’s offering. The disinfectant and antimicrobial chemicals are used to destroy harmful microorganisms such as virus, bacteria, and fungi. There are various types of disinfectants, antimicrobial chemicals available in the market, which include Phenolics, Iodophors, Nitrogen compounds, … [Read more…]

Provides Additional Financial Flexibility in Exchange for New Warrants with a $6.385 Exercise Price Company to hold a business update conference call the week of October 3rd CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it has entered into amended agreements to extend the … [Read more…]

The New LadRx Corporation Name Will Be Effective on September 26, 2022 and Will Continue to Trade Under the Ticker CYTR until the new symbol has been approved by FINRA LOS ANGELES–(BUSINESS WIRE)–CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Smart Pills Technology Market By Application, By Target Area, By Disease Indication, By End User: Global Opportunity Analysis and Industry Forecast, 2020-2030” report has been added to ResearchAndMarkets.com’s offering. The Smart Pill Technology Market size was valued at $3.2 billion in 2020 and is estimated to reach $7.5 billion by 2030, growing at … [Read more…]

Kaiser Permanente’s Mid-Atlantic region is the only plan in the nation to receive 5 out of 5 stars for Medicare, Medicaid and commercial health plans from the National Committee on Quality Assurance ROCKVILLE, Md.–(BUSINESS WIRE)–Kaiser Permanente in the Mid-Atlantic region has been named among the highest-rated health plans in the nation according to The National … [Read more…]

German biotech companies at the forefront in the development of nucleic acid-based drugs in the “Leap Innovations” category MUNICH–(BUSINESS WIRE)–On 13 September, the winners of the “Most Innovative Product” award in the category “Leap Innovations” were announced at the “Pharma Trend – Image & Innovation Award”. Cardior Pharmaceuticals came out on top, ahead of RNATICS, … [Read more…]

DALLAS–(BUSINESS WIRE)–$LTRN—Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present preclinical data on the potency of Lantern’s drug candidate LP-284 for mantle cell … [Read more…]